Enrollment Status: Open
The primary purpose of this study is to see if people with HIV who had a significant weight gain after starting INSTI (integrase strand transfer inhibitor)+TAF/FTC (tenofovir alafenamide/emtricitabine) (TAF/3TC [lamivudine]) regimen could either slow their rate of weight gain or lose weight within about 1 year if they switch to a regimen containing doravirine (DOR; a newer, non-nucleoside reverse transcriptase inhibitor medication).
Have you experienced weight gain while on antiretroviral therapy? The Do It Study is looking for people living with HIV who have experienced weight gain from taking a treatment regimen that contains an integrase inhibitor like Tivicay, Issentress, or (one of the drugs contained in Biktarvy) plus tenofovir alafenamide (TAF)
Basic Eligibility Requirement: